MJFF Collaborates on Clinical Development of Nilotinib for Parkinson’s Disease

MJFF Partners to Assess Clinical Development of Nilotinib in Parkinson's Disease

In preliminary studies, the cancer drug nilotinib has shown potential as a treatment for Parkinson's disease, but more research is needed to further test safety and long-term use.

MJFF, Van Andel Research Institute and Cure Parkinson's Trust announced plans to collaborate on the clinical assessment of nilotinib as a potential treatment for PD. Read more about this drug and its cautionary promise for Parkinson's disease, then join us for a webinar with further discussion.

  

The Michael J. Fox Foundation
Grand Central Station, P.O. Box 4777
New York, NY 10163-4777
1-800-708-7644